Jaclyn(Arquiette)WallMD

PubMed

• 2 citations
  Ineligible, Unaware, or Uninterested? Associations Between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial Enrollment.
  Nicole E Caston, Fallon Lalor, Jaclyn Wall, Jesse Sussell, Shilpen Patel, Courtney P Williams, Andres Azuero, Rebecca Arend, Margaret I Liang, Gabrielle B Rocque> ;JCO Oncology Practice. 2022 Nov 1
• 3 citations
  Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
  Margaret I Liang, J Leahgrace Simons, Ivan I Herbey, Jaclyn A Wall, Lindsay R Rucker, Nataliya V Ivankova, Warner K Huh, Maria Pisu> ;Gynecologic Oncology. 2022 Sep 1
• 4 citations
  Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
  Jaclyn A Wall, Kelsey Lipking, Haller J Smith, Warner K Huh, Terri Salter, Margaret I Liang> ;Gynecologic Oncology. 2022 Sep 1
• 8 citations
  Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a p...
  Rebecca C. Arend, Nidhi Goel, Brandon M. Roane, McKenzie E. Foxall, Jhalak Dholakia, Angelina I. Londono, Jaclyn A. Wall, Charles A. Leath, Warner K. Huh> ;Gynecologic Oncology. 2021 Aug 6
• 6 citations
  Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance
  Nidhi Goel, McKenzie E. Foxall, Carly Bess Scalise, Jaclyn A. Wall, Rebecca C. Arend> ;Molecular Cancer Therapeutics. 2021 Jun 25
• 25 citations
  Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
  Jaclyn A. Wall, Selene Meza-Perez, Carly Bess Scalise, Ashwini A. Katre, Angelina I. Londono, William J. Turbitt, Troy D. Randall, Lyse A. Norian, Rebecca C. Arend> ;Gynecologic Oncology. 2021 Jan 1
• Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774].
  Ilaria Betella, William J. Turbitt, Tomasz Szul, BinghaoWu, Alba Martinez, Ashwini A. Katre, Jaclyn A. Wall, Lyse A. Norian, Michael J. Birrer, Rebecca C. Arend> ;Gynecologic Oncology. 2020 Aug 21
• 37 citations
  Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
  Ilaria Betella, William J. Turbitt, Tomasz Szul, Binghao Wu, Alba Martinez, Ashwini A. Katre, Jaclyn A. Wall, Lyse A. Norian, Michael J. Birrer, Rebecca C. Arend> ;Gynecologic Oncology. 2020 Jun 1
• 37 citations
  The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
  Jaclyn A. Wall, Samuel J. Klempner, Rebecca C. Arend> ;Expert Opinion on Investigational Drugs. 2020 May 25
• 14 citations
  Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
  Rebecca C. Arend, Hannah M. Beer, Yael C Cohen, Suzanne Berlin, Michael J. Birrer, Susana M. Campos, Tamar Rachmilewitz Minei, Dror Harats, Jaclyn A. Wall, McKenzie E....> ;Gynecologic Oncology. 2020 Apr 5
• 1 citations
  Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer.
  Jaclyn A. Wall, Rebecca C. Arend> ;Annals of Translational Medicine. 2020 Mar 31
• 15 citations
  Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment.
  Whitney N. Goldsberry, Selene Meza-Perez, Angelina I. Londono, Ashwini A. Katre, Bryan T. Mott, Brandon M. Roane, Nidhi Goel, Jaclyn A. Wall, Sara J. Cooper, Lyse A. N...> ;Cancers. 2020 Mar 24
• Join now to see all